Dr Brendon Neuen is a nephrology registrar and NHMRC Scholar at The George Institute for Global Health, Australia. He is a recognised expert on the efficacy and safety of SGLT2 inhibitors in people with diabetes and chronic kidney disease, having led several analyses of the CANVAS and CREDENCE trials. He is regularly invited to speak at national and international meetings on the topic of SGLT2 inhibition and diabetic kidney disease. Dr Neuen is involved in several ongoing international multi-centre randomized trials and has published over 80 peer-reviewed articles, which have directly informed major international clinical practice guidelines which define best practice for the care of people with type 2 diabetes and kidney disease, including the Kidney Disease Improving Global Outcomes (KDIGO) Guidelines and the American Diabetes Association (ADA) Standards of Care.